OncosphereExplore Cancer Insights and Innovations Today
Stay informed on cancer history, treatments, and the latest research breakthroughs and trials.
Read the latest →ESMO 2026 Madrid →
ESMO 2026 trial hub · ESMO 2026 week update (2–6 Nov) · ESMO 2026 trial matching game · Best of cancer media: top threads, papers, interviews · Presidential Symposium I: INTerpath-001, VOLGA, DeLLphi-305, DASL-HiCaP · Presidential Symposium II: Krascendo 1, SAFFRON, CLARITY-Gastric 01, HARMONi-GI1 · Trial briefs: ATOMIC, HER2CLIMB-05, PSMAddition, EXCALIBER-RRMM, BRUIN CLL-313
Latest in oncology
- Cascade DNA walker-driven photo-controlled CRISPR/Cas12a nanorobot enabling ultrasensitive one-pot detection of dual miRNAs in triple-negative breast cancer.
- Thermosensitive and tumor-targeted asparaginase fusion protein enables metabolic-immunotherapy for solid tumors.
- Cytotoxic T lymphocyte-inspired nanotherapeutics chaperoning granzyme B for tumor immune remodeling.
- Genetically engineering mast cells as effectors for targeted cancer cell cytotoxicity.
- An aggregation-induced emission fluorescent microsphere-based intelligent lateral flow immunosensor for rapid and quantitative detection of prostate-specific antigen.
Cancer treatment paradigms →
First-line therapy · Lung · Breast · GI · Bladder · Sarcoma · Dostarlimab · Trial briefs · FDA approvals
ConferenceSITC 2026 (Phoenix, 4–8 Nov): three early-phase immunotherapy signals worth knowing
IL-2-free engineered TIL (amsoki-cel) in ICI-resistant melanoma: ORR 67% (10/15). Two T-cell engagers together (brenetafusp + tebentafusp) in first-line uveal melanoma: 2-year OS 70% (n=17). PD-1×VEGF bispecific cesalatamig alone after IO in NSCLC: ORR 33% at 10 mg/kg (n=21). All early phase, single-arm, small.
PerspectiveEGFR-mutant NSCLC after osimertinib: the 2026 phase 3 evidence, ahead of the 14 Nov FDA decision
Four randomised phase 3 trials now test new options against platinum–pemetrexed after third-generation EGFR TKI failure: SAFFRON (osimertinib + savolitinib, MET-driven), HERON-Lung01 (HER3 ADC), PANKU-Lung01 (EGFR×HER3 bispecific ADC) and HARMONi (ivonescimab + chemo, FDA decision 14 Nov). Only SAFFRON has a statistically significant OS gain so far.
ApprovalsRybrevant Faspro for pretreated head and neck cancer: FDA accelerated approval, 5 November 2026
FDA accelerated approval of subcutaneous amivantamab plus hyaluronidase (Rybrevant Faspro) for adults with recurrent or metastatic HNSCC after platinum chemotherapy and a PD-(L)1 antibody. OrigAMI-4 (n=102): ORR 42% (95% CI 32–52%); 56% of responders lasted at least 6 months. Not indicated for HPV-associated oropharyngeal cancer.
NewsThree oncology FDA decisions to watch in November 2026
FDA target dates this month: ivonescimab + chemo after EGFR-TKI failure (14 Nov), neladalkib in TKI-pretreated ALK+ NSCLC (27 Nov) and adjuvant giredestrant in ER+/HER2- early breast cancer (30 Nov).
TrialESMO 2026 in NEJM: HEALER (HER2+ breast) and OptiTROP-Lung06 (PD-L1-negative NSCLC)
Two China-run phase 3 trials published in NEJM with ESMO 2026: anbenitamab + albumin-bound docetaxel beats THP in first-line HER2+ advanced breast cancer (HR 0.46), and sacituzumab tirumotecan + pembrolizumab beats chemo-IO in PD-L1 <1% non-squamous NSCLC (PFS 15.0 vs 5.7 mo; HR 0.49).
ConferenceESMO 2026 Presidential Symposium II: KRAS G12C, EGFR/MET lung, CLDN18.2 gastric and biliary
Krascendo 1, SAFFRON, CLARITY-Gastric 01 and HARMONi-GI1 all improved overall survival against active comparators.
ConferenceESMO 2026 Presidential Symposium I: melanoma vaccine, bladder, SCLC and prostate
Four positive phase 3 late-breakers from Madrid — INTerpath-001, VOLGA, DeLLphi-305 and DASL-HiCaP. Two showed overall survival gains at interim analysis.
ConferenceESMO Congress 2026 in Madrid: what to watch
ESMO 2026 runs 23–27 October in Madrid. Presidential Symposia are on Saturday 24 and Sunday 25 October.
ApprovalsFDA oncology approvals, October 2026: a roundup
Pirtobrutinib in first-line CLL, tucatinib maintenance in HER2+ breast cancer, adjuvant atezolizumab for dMMR colon cancer, talazoparib-enzalutamide in HRR-mutated mHSPC and more.
ApprovalsDostarlimab gets FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer
On 19 October 2026 the FDA granted accelerated approval to dostarlimab for Stage II/III MSI-H or dMMR rectal cancer.
TrialsTrial briefs, October 2026: approvals, breast, GU, gynae, myeloma and HER2 rulebook
Telegraphic trial-by-trial briefs from Dr. Senthil Kumar's October 2026 X threads — ATOMIC, HER2CLIMB-05, NRG-BR002, PSMAddition, EXCALIBER-RRMM, BRUIN CLL-313, DESTINY-Breast11 and more.
ConferenceAsco gi 2026
ASCO GI 2026 (San Francisco, 8–10 Jan): HERIZON-GEA-01, BREAKWATER FOLFIRI cohort and COMMIT.
TrialsDESTINY BREAST 11 TRIAL
Neoadjuvant T-DXd → THP raised pCR to 67.3% vs 56.3% with ddAC-THP in high-risk HER2+ early breast cancer, with less toxicity.
TrialsFlaura 2 trial
Osimertinib + platinum–pemetrexed: final OS 47.5 vs 37.6 months vs osimertinib alone in EGFR-mutant advanced NSCLC.
TrialsDEFI Trial: Nirogacestat for Desmoid Tumors
Phase 3 DeFi: oral γ-secretase inhibitor nirogacestat cut the risk of progression by 71% in progressing desmoid tumours.
Treatment paradigmsAdvanced Bladder / Urothelial cancer
Explore cancer history, treatments, and latest research.
Treatment paradigmsFirst-Line Systemic Therapy in Advanced Cancers
Choosing the right first-line systemic therapy is crucial in managing advanced cancers.
Historical Perspectives →
Explore the evolving understanding of cancer through history, from early theories to modern advancements, shaping the way we diagnose, treat, and research this complex disease.
- 1890s — Halsted and Beatson: surgery and hormones
- 1896–1900s — From shadows to light: X-rays, radium and radiotherapy
- 1917–1930s — The Radium Girls
- 1940s — Nitrogen mustard and Farber's antifolates
- 1978 — Cisplatin and testicular cancer
- 1998 — Trastuzumab: targeted therapy arrives
- 2001 — Imatinib for CML
- 2006 — HPV vaccine
- 2011 — Ipilimumab: checkpoint era
- 2017 — Tissue-agnostic: MSI-H/dMMR
- 2020s — ADCs, organ preservation, ctDNA
15
Trusted by Professionals
Expert Guidance
17
Posts
with sources
4
Guideline bodies
NCCN · ESMO · ASCO · ICMR
Empowering Cancer Awareness and Research
Oncosphere is dedicated to providing insightful information on cancer history, treatments, future trends, and the latest research to empower patients and families in their journey.
India registered an estimated 14.6 lakh new cancer cases in 2022 (ICMR–National Cancer Registry Programme projection; Sathishkumar et al., Indian J Med Res 2022). Every post here ends with what the evidence means for patients treated in Indian public and private hospitals.
Gallery →
Explore visual insights on cancer research, treatments, and future trends. Open the gallery →
General Medical Topics →
Sharing thoughtful discussions on medical topics that matter to oncologists and their patients.
Vaccination during chemotherapy · Febrile neutropenia at home · Onco-cardiology basics · CMCHIS / PM-JAY coverage
135
Trusted Source
Primary references cited across posts (journals, FDA, guidelines)
Get in Touch
We welcome your inquiries and feedback regarding cancer research, treatments, and our blog. Connect with us to share your thoughts.
Support
Curated by Dr. Senthil Kumar. Contact